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Abstract
Non-prescriptional use of medicinal herbs among cancer patients is common around the world.
The alleged anti-cancer effects of most herbal extracts are mainly based on studies derived from in
vitro or in vivo animal experiments. The current information suggests that these herbal extracts
exert their biological effect either through cytotoxic or immunomodulatory mechanisms. One of
the active compounds responsible for the immune effects of herbal products is in the form of
complex polysaccharides known as β-glucans. β-glucans are ubiquitously found in both bacterial or
fungal cell walls and have been implicated in the initiation of anti-microbial immune response. Based
on in vitro studies, β-glucans act on several immune receptors including Dectin-1, complement
receptor (CR3) and TLR-2/6 and trigger a group of immune cells including macrophages,
neutrophils, monocytes, natural killer cells and dendritic cells. As a consequence, both innate and
adaptive response can be modulated by β-glucans and they can also enhance opsonic and non-
opsonic phagocytosis. In animal studies, after oral administration, the specific backbone 1→3 linear
β-glycosidic chain of β-glucans cannot be digested. Most β-glucans enter the proximal small
intestine and some are captured by the macrophages. They are internalized and fragmented within
the cells, then transported by the macrophages to the marrow and endothelial reticular system.
The small β-glucans fragments are eventually released by the macrophages and taken up by other
immune cells leading to various immune responses. However, β-glucans of different sizes and
branching patterns may have significantly variable immune potency. Careful selection of appropriate
β-glucans is essential if we wish to investigate the effects of β-glucans clinically. So far, no good
quality clinical trial data is available on assessing the effectiveness of purified β-glucans among cancer
patients. Future effort should direct at performing well-designed clinical trials to verify the actual
clinical efficacy of β-glucans or β-glucans containing compounds.
Introduction
A significant proportion of cancer patients have been tak-
ing complementary medical therapies while receiving
their conventional anti-cancer treatments [1-6]. Among
them, herbal extracts such as Ganoderma lucidum are one
of the most common modalities being consumed espe-
cially among Oriental [7-10]. Two mechanisms have been
proposed to be responsible for the anti-cancer action of
these herbal extracts; one is via direct cytotoxic effect and
the other is indirectly through immunomodulatory action
[11,12]. Many cytotoxic chemotherapeutic agents cur-
rently in use such as vincristine, taxol and etoposide are
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originally purified from herbs. On the other hand, herbs
with immunomodulatory functions have mainly been
advocated by commercial sectors and most of them can be
directly purchased over the counter or the internet. Unfor-
tunately, organized efforts to investigate the actual useful-
ness of this group of herbs as well as their active
ingredients are lacking. In recent years, one of the active
ingredients responsible for the immunomodulation of
many of these herbs was found to be a form of complex
polysaccharides known as "β-D-glucan", or simply called
β-glucan [8,13]. The receptors and mechanisms of action
of β-glucans have recently been unfolded via in vitro and
in vivo animal experiments. Since β-glucans are inexpen-
sive and have good margin of safety based on historical
track records, their potential therapeutic value deserve fur-
ther investigation. We reviewed here the literature and our
experience on the in vitro and in vivo animal biological
studies of β-glucans, particularly on their immune and
anti-cancer mechanisms.
Physical and chemical properties of β-glucan
β-glucans are one of the most abundant forms of polysac-
charides found inside the cell wall of bacteria and fungus.
All β-glucans are glucose polymers linked together by a
1→ 3 linear β-glycosidic chain core and they differ from
each other by their length and branching structures [14]
(Figure 1). The branches derived from the glycosidic chain
core are highly variable and the 2 main groups of branch-
ing are 1→4 or 1→6 glycosidic chains. These branching
assignments appear to be species specific, for example, β-
glucans of fungus have 1→6 side branches whereas those
of bacteria have 1→4 side branches. The alignments of
branching follow a particular ratio and branches can arise
from branches (secondary branches). In aqueous solu-
tion, β-glucans undergo conformational change into tri-
ple helix, single helix or random coils. The immune
functions of β-glucans are apparently dependent on their
conformational complexity [15]. It has been suggested
that higher degree of structural complexity is associated
with more potent immunmodulatory and anti-cancer
effects.
For research purposes, the composition or structural
information of β-glucans can be evaluated by a variety of
methods including liquid chromatography/mass spec-
trometry (LC/MS)[16], high performance liquid chroma-
tography (HPLC)[17] and less often X-ray crystallography
[18] or atomic force microscopy [19]. However, due to the
tedious and lack of quantitative nature of most of these
technical methods, they cannot be applied routinely as a
screening tool. Other less sophisticated techniques in
studying the β-glucans contents include phenol-sulphuric
acid carbohydrate assay, aniline blue staining method and
ELISA. Because chemical modification invariably induces
changes in the natural conformation, most of these meth-
ods cannot reflect the genuine relationship between the
structure and the bioactivity. Among them, aniline blue
staining method is a relatively simple method to screen
for β-glucan because of its ability to retain the natural con-
formation of β-glucans during the staining process. It also
has a good specificity for β-glucans but its limitation is
that it can only measure the core 1→3 linear glycosidic
chain and not the branches.
Endotoxin contamination is another important issue
affecting the safety and potential biological effect of β-glu-
can. Lipopolysaccharide (LPS) is an endotoxin found
inside the Gram negative bacterial cell wall and consists of
three main parts including lipid A, core and polysaccha-
ride chain [20]. Among them, lipid A was found to be the
major component that can initiate an immune response.
LPS contamination can occur during the culture or prepa-
ration of β-glucans. Since LPS is one of the most potent
immune stimulator and its contamination can lead to
false positive results in immune tests, quantification of
LPS should be performed, which can be evaluated by
either the rabbit pyrogen test or the modified limulus
amebocyte lysate (LAL) assay with devoid factor G [21].
Pharmacodynamics & Pharmacokinetics of β-glucan
Most β-glucans are considered as non-digestible carbohy-
drates and are fermented to various degrees by the intesti-
nal microbial flora [22-24]. Therefore, it has been
speculated that their immunomodulatory properties may
be partly attributed to a microbial dependent effect. How-
ever, β-glucans in fact can directly bind to specific recep-
tors of immune cells, suggesting a microbial independent
immunomodulatory effect [25]. The pharmacodynamics
and pharmacokinetics of β-glucans have been studied in
animal and human models.
Animal Studies
Study using a suckling rat model for evaluation of the
absorption and tissues distribution of enterally adminis-
tered radioactive labeled β-glucan, it was found that the
majority of β-glucan was detected in the stomach and
duodenum 5 minutes after the administration [26]. This
amount rapidly decreased during first 30 minutes. A sig-
nificant amount of β-glucan entered the proximal intes-
tine shortly after ingestion. Its transit through the
proximal intestine decreased with time with a simultane-
ous increase in the ileum. Despite low systemic blood lev-
els (less than 0.5%), significant systemic
immunomodulating effects in terms of humoral and cel-
lular immune responses were demonstrated.
The pharmacokinetics following intravenous administra-
tion of 3 different highly purified and previously charac-
terized  β-glucans were studied using carbohydrates
covalently labeled with a fluorophore on the reducing ter-Journal of Hematology & Oncology 2009, 2:25 http://www.jhoonline.org/content/2/1/25
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minus. The variations in molecular size, branching fre-
quency and solution conformation were shown to have
an impact on the elimination half-life, volume of distribu-
tion and clearance [27].
The low systemic blood level of β-glucans after ingestion
does not reflect the full picture of the pharmacodynamics
of β-glucans and does not rule out its in vivo effects. Che-
ung-VKN et al. labeled β-glucans with fluorescein to track
their oral uptake and processing in vivo. The orally admin-
istered β-glucans were taken up by macrophages via the
Dectin-1 receptor and was subsequently transported to
the spleen, lymph nodes, and bone marrow. Within the
bone marrow, the macrophages degraded the large β-1,3-
glucans into smaller soluble β-1,3-glucan fragments.
These fragments were subsequently taken up via the com-
β-glucan is one of the key components of the fungal cell wall Figure 1
β-glucan is one of the key components of the fungal cell wall. The basic subunit of the fungal β-glucan is β-D-glucose 
linked to one another by 1→3 glycosidic chain with 1→6 glycosidic branches. The length and branches of the β-glucan from 
various fungi are widely different.Journal of Hematology & Oncology 2009, 2:25 http://www.jhoonline.org/content/2/1/25
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plement receptor 3 (CR3) of marginated granulocytes.
These granulocytes with CR3-bound β-glucan-fluorescein
were shown to kill inactivated complement 3b (iC3b)-
opsonized tumor cells after they were recruited to a site of
complement activation such as tumor cells coated with
monoclonal antibody [28] (Figure 2). It was also shown
that intravenous administered soluble β-glucans can be
delivered directly to the CR3 on circulating granulocytes.
Furthermore, Rice PJ et al. showed that soluble β-glucans
such as laminarin and scleroglucan can be directly bound
and internalized by intestinal epithelial cells and gut asso-
ciated lymphoid tissue (GALT) cells [29]. Unlike macro-
phage, the internalization of soluble β-glucan by
intestinal epithelial cells is not Dectin-1 dependent. How-
ever, the Dectin-1 and TLR-2 are accountable for uptake of
soluble β-glucan by GALT cells. Another significant find-
ing of this study is that the absorbed β-glucans can
increase the resistance of mice to bacterial infection chal-
lenge.
Human Studies
How  β-glucans mediate their effects after ingestion in
human remained to be defined. In a phase I study for the
assessment of safety and tolerability of a soluble form oral
β-glucans [30]. β-glucans of different doses (100 mg/day,
200 mg/day or 400 mg/day) were given respectively for 4
consecutive days. No drug-related adverse events were
observed. Repeated measurements of β-glucans in serum,
however, revealed no systemic absorption of the agent fol-
lowing the oral administration. Nonetheless, the immu-
noglobulin A concentration in saliva increased
significantly for the 400 mg/day arm, suggesting a sys-
temic immune effect has been elicited. One limitation of
this study is the low sensitivity of serum β-glucans deter-
mination.
In summary, based on mostly animal data, β-glucans
enter the proximal small intestine rapidly and are cap-
tured by the macrophages after oral administration. The β-
glucans are then internalized and fragmented into smaller
sized  β-glucans and are carried to the marrow and
endothelial reticular system. The small β-glucans frag-
ments are then released by the macrophages and taken up
by the circulating granulocytes, monocytes and dendritic
cells. The immune response will then be elicited. How-
ever, we should interpret this information with caution as
most of the proposed mechanisms are based on in vitro
The uptake and subsequent actions of β-glucan on immune cells Figure 2
The uptake and subsequent actions of β-glucan on immune cells. β-glucans are captured by the macrophages via the 
Dectin-1 receptor with or without TLR-2/6. The large β-glucan molecules are then internalized and fragmented into smaller 
sized β-glucan fragments within the macrophages. They are carried to the marrow and endothelial reticular system and subse-
quently released. These small β-glucan fragments are eventually taken up by the circulating granulocytes, monocytes or macro-
phages via the complement receptor (CR)-3. The immune response will then be turned on, one of the actions is the 
phagocytosis of the monoclonal antibody tagged tumor cells.Journal of Hematology & Oncology 2009, 2:25 http://www.jhoonline.org/content/2/1/25
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and in vivo animal studies. Indeed, there is little to no evi-
dence for these hypothesized mechanisms of action and
pharmacokinetics occurred in human subjects at the
moment.
β-glucans as immunomodulating agent
Current data suggests that β-glucans are potent immu-
nomodulators with effects on both innate and adaptive
immunity. The ability of the innate immune system to
quickly recognize and respond to an invading pathogen is
essential for controlling infection. Dectin-1, which is a
type II transmembrane protein receptor that binds β-1,3
and β-1,6 glucans, can initiate and regulate the innate
immune response [31-33]. It recognizes β-glucans found
in the bacterial or fungal cell wall with the advantage that
β-glucans are absent in human cells. It then triggers effec-
tive immune responses including phagocytosis and proin-
flammatory factors production, leading to the elimination
of infectious agents [34,35]. Dectin-1 is expressed on cells
responsible for innate immune response and has been
found in macrophages, neutrophils, and dendritic cells
[36]. The Dectin-1 cytoplasmic tail contains an immu-
noreceptor tyrosine based activation motif (ITAM) that
signals through the tyrosine kinase in collaboration with
Toll-like receptors 2 and 6 (TLR-2/6) [34,37,38]. The
entire signaling pathway downstream to dectin-1 activa-
tion has not yet been fully mapped out but several signal-
ing molecules have been reported to be involved. They are
NF-κB (through Syk-mediate pathway), signaling adaptor
protein CARD9 and nuclear factor of activated T cells
(NFAT) [39-41] (Fig. 3). This will eventually lead to the
release of cytokines including interleukin (IL)-12, IL-6,
tumor necrosis factor (TNF)-α, and IL-10. Some of these
cytokines may play important role in the cancer therapy.
On the other hand, the dendritic cell-specific ICAM-3-
grabbing non-integrin homolog, SIGN-related 1
(SIGNR1) is another major mannose receptor on macro-
phages that cooperates with the Dectin-1 in non-opsonic
recognition of β-glucans for phagocytosis [42] (Fig 3).
Furthermore, it was found that blocking of TLR-4 can
inhibit the production of IL-12 p40 and IL-10 induced by
purified Ganoderma glucans (PS-G), suggesting a vital
role of TLR-4 signaling in glucan induced dendritic cells
maturation. Such effect is also operated via the augmenta-
tion of the IκB kinase, NF-κB activity and MAPK phospho-
rylation [43]. One additional point to note is that those
studies implied the interaction between β-glucans and
TLR all used non-purified β-glucans, therefore the actual
involvement of pure β-glucans and TLR remains to be
proven.
Other possible receptors and signaling pathways induced
by β-glucans are less definite at the moment. For example,
lentinan, a form of mushroom derived β-glucans, has
been found to bind to scavenger receptor found on the
surface of myeloid cells and triggers phosphatidylinositol-
3 kinase (PI3K), Akt kinase and p38 mitogen-activated
protein kinase (MAPK) signaling pathway [44](Fig. 3).
But no specific β-glucans scavenger receptor has been
identified so far. Candida albicans derived β-glucans but
not other forms of pathogenic fungal β-glucans can bind
to LacCer receptor and activate the PI-3K pathway in con-
trolling the neutrophil migration [45] (Fig. 3), but such
activation pathway may involve other molecules found in
the Candida derived β-glucans.
We found that β-glucans can induce human peripheral
blood mononuclear cells proliferation [46]. It can also
enhance phenotypic and functional maturation of mono-
cyte derived dendritic cells with significant IL-12 and IL-
10 production. Similar findings were found by Lin et al.
using PS-G, in addition, treatment of dendritic cells with
PS-G resulted in enhanced T cell-stimulatory capacity and
increased T cell secretion of interferon-γ and IL-10
[43,47]. This action is at least mediated in part through
the Dectin-1 receptor. The potency of such immunomod-
ulating effects differs among β-glucans and purified
polysaccharides of different size and branching complex-
ity. In general, bigger size and more complex β-glucans
such as those derived from Ganoderma lucidum have
higher immunomodulating potency.
The adaptive immune system functions through the com-
bined action of antigen-presenting cells and T cells. Spe-
cifically, class I major histocompatibility complex (MHC-
I) antigen presentation to CD8(+) cytotoxic T cells is lim-
ited to proteosome-generated peptides from intracellular
pathogens. On the other hand, the class II MHC (MHC-II)
endocytic pathway presents only proteolytic peptides
from extracellular pathogens to CD4(+) T helper cells.
Carbohydrates have been previously thought to stimulate
immune responses independently of T cells [48]. How-
ever, zwitterionic polysaccharides (polysaccharides that
carry both positive and negative charges) such as β-glu-
cans can activate CD4(+) T cells through the MHC-II
endocytic pathway [49]. β-glucans are processed to low
molecular weight carbohydrates by a nitric oxide-medi-
ated mechanism. These carbohydrates will then bind to
MHC-II inside antigen-presenting cells such as dendritic
cells for presentation to T helper cells. Initial data sug-
gested that it subsequently leads to Th-1 response, but
there are conflicting data related to this aspect. In our in
vitro data, β-glucans do not tend to polarize T cells into
either Th-1, Th-2 or regulatory T cells [46]. However,
recent publications suggested β-glucans such as zymosan
may induce T-cells into T-reg cells in a NOD mice model
[50]. Therefore, whether β-glucans can induce important
immunologic responses through T cell activation remain
to be further investigated.Journal of Hematology & Oncology 2009, 2:25 http://www.jhoonline.org/content/2/1/25
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Immune activation induced by β-glucans Figure 3
Immune activation induced by β-glucans. β-glucans can act on a variety of membrane receptors found on the immune 
cells. It may act singly or in combine with other ligands. Various signaling pathway are activated and their respective simplified 
downstream signaling molecules are shown. The reactors cells include monocytes, macrophages, dendritic cells, natural killer 
cells and neutrophils. Their corresponding surface receptors are listed. The immunomodulatory functions induced by β-glucans 
involve both innate and adaptive immune response. β-glucans also enhance opsonic and non-opsonic phagocytosis and trigger a 
cascade of cytokines release, such as tumor necrosis factor(TNF)-α and various types of interleukins (ILs).Journal of Hematology & Oncology 2009, 2:25 http://www.jhoonline.org/content/2/1/25
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Another mechanism of β-glucan action is mediated via
the activated complement receptor 3 (CR3, also known as
CD11b/CD18), which is found on natural killer (NK)
cells, neutrophils, and lymphocytes. This pathway is
responsible for opsonic recognition of β-glucans leading
to phagocytosis and reactor cells lysis. β-glucans bind to
the lectin domain of CR3 and prime it for binding to inac-
tivated complement 3b (iC3b) on the surface of reactor
cells. The reactor cells can be of any cell type including
cancer cells tagged with monoclonal antibody and coated
with iC3b. The β-glucans-activated circulating cells such
as the CR3 containing neutrophils will then trigger cell
lysis on iC3b-coated tumor cells [28]. Similarly, majority
of the human NK cells express CR3 and it was shown that
opsonization of NK cells coated with iC3b leads to an
increase in the lysis of the target. The beta chain of the
CR3 molecule (CD18) rather than the alpha chain
(CD11b) is responsible to the β-glucan binding [51,52].
This concept was supported by in vivo study demonstrat-
ing barley β-1,3;1,4-glucan given orally can potentiate the
activity of an antitumor monoclonal antibody (anti-gan-
glioside-2 or "3F8"), leading to enhanced tumor regres-
sion and survival on a human neuroblastoma xenografts
mouse model [53]. 3F8 plus β-glucan was shown to pro-
duce near-complete tumor regression or disease stabiliza-
tion whereas 3F8 or β-glucan alone showed no significant
effect. The median survival of the 3F8 plus β-glucan group
was 5.5-fold higher than that of the control groups, and
up to 47% of the mice remained progression free in con-
trast to <3% of controls at the end of the study period. No
toxicities were noted in all mice treated with β-glucan,
3F8, or 3F8 plus β-glucan.
A similar xenograft model was adopted subsequently for
investigating various targeted tumor antigens and tumor
types. It was found that β-glucan exerts similar anti-tumor
effects irrespective of antigens (GD2, GD3, CD20, epider-
mal growth factor-receptor, and HER-2) or human tumor
types (neuroblastoma, melanoma, lymphoma, epider-
moid carcinoma, and breast carcinoma) or tumor sites
(subcutaneous versus systemic). The effect was correlated
with the molecular size of the β-1,3;1,4-glucan [53,54].
Furthermore, 2 other receptors known as scavenger [55]
and lactosylceramide [56,57] also bind β-glucans and can
elicit a range of responses. β-glucans can enhance endo-
toxin clearance via scavenger receptors by decreasing TNF
production leading to improved survival in rats subjected
to Escherichia coli sepsis [58]. On the other hand, β-glu-
cans binding to lactosylceramide receptor can enhance
myeloid progenitor proliferation and neutrophil oxida-
tive burst response, leading to an increase in leukocyte
anti-microbial activity. It is also associated with the activa-
tion of NF-κB in human neutrophils [59]. Again in other
studies, structurally different β-glucans appear to have dif-
ferent affinity toward these receptors. For example, only
high molecular weight β-glucans can effectively bind to
the lactosylceramide receptor. Therefore, markedly differ-
ent host responses induced by different β-glucans are
expected.
In summary, β-glucans act on a diversity of immune
related receptors in particularly Dectin-1 and CR3, and
can trigger a wide spectrum of immune responses. The tar-
geted immune cells of β-glucans include macrophages,
neutrophils, monocytes, NK cells and dendritic cells (Fig-
ure 3). The immunomodulatory functions induced by β-
glucans involve both innate and adaptive immune
response.  β-glucans also enhance opsonic and non-
opsonic phagocytosis. Whether β-glucans polarize the T
cells subset towards a particular direction remains to be
explored.
Anti-cancer effects of β-glucans
It is becoming clear that β-glucans themselves have no
direct cytotoxic effects. Studies implicating the cytotoxic
effects of β-glucans were either from studies using crude
extracts of β-glucan containing herbs or the use of β-glu-
can primed monocytes. For β-glucan containing herbs like
Ganoderma lucidum (Lingzhi), there are other active com-
ponents such as ganoderic acid from its mycelium [60]
and triterpenes from its spore [61-63], which have all
been shown to have direct anti-cancer effects independ-
ently. We did not find any direct cytotoxic effects of β-glu-
cans on a panel of common cancer cell lines tested
including carcinoma, sarcoma, and blastoma. β-glucans
also did not trigger any apoptotic pathways and had no
direct effect on the telomerase and telomeric length of the
cancer cells (unpublished data). In contrast, it stimulated
the proliferation of monocytic lineage leukemic cells in-
vitro and can facilitate the maturation of dendritic cells
derived from leukaemic cells [64]. Hence, whether it is
beneficial to apply β-glucans on leukemic patients
remains controversial and has to be considered with cau-
tion.
In the English literature, there are no clinical trials that
directly assessed the anti-cancer effects of purified β-glu-
cans in cancer patients. Most studies were assessing the
toxicity profile or underlying immune changes of the can-
cer patients without addressing on the change of cancer
status. In addition, most of the related studies used either
crude herbal extracts or a fraction of the extracts instead of
purified  β-glucans. Therefore, it is difficult to identify
whether the actual effects were related to β-glucans or
other confounding chemicals found in the mixture.
In a prospective clinical trial of short term immune effects
of oral β-glucan in patients with advanced breast cancer,Journal of Hematology & Oncology 2009, 2:25 http://www.jhoonline.org/content/2/1/25
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23 female patients with advanced breast cancer were com-
pared with 16 healthy females control [65]. Oral β-
1,3;1,6-glucan was taken daily. Blood samples were recol-
lected on the day 0 and 15. It was found that despite a rel-
atively low initial white cell count, oral β-glucan can
stimulate proliferation and activation of peripheral blood
monocytes in patients with advanced breast cancer.
Whether that can be translated into clinical benefit
remains unanswered.
Clinical trials on anti-cancer effects of natural products 
with β-glucan
Many edible fungi particularly in the mushroom species
yield immunogenic substances with potential anticancer
activity [66]. β-glucans are one of the common active
components (Table 1). In limited clinical trials on human
cancers, most were well tolerated. Among them, lentinan
derived from Lentinus edodes is a form of β-glucans [67].
Since it has poor enteric absorption, intrapleural, intra-
peritoneal [68] or intravenous routes had been adopted in
clinical trials which showed some clinical benefit when
used as an adjuvant to chemotherapy [69]. Schizophyllan
(SPG) or sizofiran is another β-glucan derived from Schiz-
ophyllan commune. Its triple helical complex β-glucans
structure prevents it from adequate oral absorption so an
intratumoral route or injection to regional lymph nodes
had been adopted [70,71]. In a randomized trial, SPG
combined with conventional chemotherapy improved
the long term survival rate of patients with ovarian cancer
[72]. But whether the prolonged survival can subse-
quently led to a better cure rate remain unanswered.
Maitake D-Fraction extracted from Grifola frondosa
(Maitake mushroom) was found to decrease the size of
the lung, liver and breast tumors in >60% of patients
when it was combined with chemotherapy in a 2 arms
control study comparing with chemotherapy alone [73].
The effects were less obvious with leukemia, stomach and
brain cancer patients [74]. But the validity of the clinical
study was subsequently questioned by another independ-
ent observer [75]. Two proteoglycans from Coriolus versi-
color  (Yun Zhi) – PSK (Polysaccharide-K) and PSP
(Polysaccharopeptide) – are among the most extensively
studied  β-glucan containing herbs with clinical trials
information. However, both PSK and PSP are protein-
bound polysaccharides, so their actions are not necessary
directly equivalent to pure β-glucans [76]. In a series of tri-
als from Japan and China, PSK and PSP were well toler-
ated without significant side effects [66,77-81]. They also
prolonged the survival of some patients with carcinoma
and non-lymphoid leukemia.
Ganoderma  polysaccharides are β-glucans derived from
Ganoderma lucidum (Lingzhi, Reishi). While β-glucan is
the major component of the Ganoderma mycelium, it is
only a minor component in the Ganoderma spore [7].
The main active ingredient in the Ganoderma spore extract
is triterpenoid which is cytotoxic in nature. In an open-
label study on patients with advanced lung cancer, thirty-
six patients were treated with 5.4 g/day Ganoderma
polysaccharides for 12 weeks with inconclusive variable
and results on the cytokines profiles [82]. Another study
on 47 patients with advanced colorectal cancer using the
Table 1: Selected Medicinal Mushroom with β-glucans as Active Components
Herbs Common Name β-glucans structure Types of β-glucans
Lentinus edodes Shiitake mushroom β-1,3;1,6-glucan Lentinan
Schizophyllan commune Brazilian mushroom, Schizophyllan β-1,3;1,6-glucan Schizophyllan (SPG) or sizofiran
Grifola frondosa Maitake mushroom β-1,3;1,6-glucan with xylose and 
mannose
Maitake D-Fraction
Coriolus versicolor Yun Zhi Protein bound β-1,3;1,6-glucan PSP (polysaccharide peptide) PSK 
(polysaccharide-Kureha or polysaccharide-K, 
krestin)
Ganoderma lucidum Lingzhi, Reishi β-1,3;1,6-glucan Ganoderma polysaccharides, Ganopoly
Agaricus blazei Brazilian sun-mushroom, 
Himematsutake mushroom
Protein bound β-1,6-glucan Agaricus polysaccharides
Pleurotus ostreatus Oyster mushroom, píng gû β-1,3-glucan with galactose and 
mannose
Pleuran
Coprinus comatus Shaggy ink cap, lawyer's wig, or 
shaggy mane
β-1,3-glucan Coprinus polysaccharidesJournal of Hematology & Oncology 2009, 2:25 http://www.jhoonline.org/content/2/1/25
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same dosage and period again demonstrated similar vari-
able immune response patterns [83]. These results high-
light the inconsistency of clinical outcomes in using
immune enhancing herbal extracts clinically, which may
partly be due to the impurity of the products used.
Conclusion
The intrinsic differences of the β-glucans derived from dif-
ferent sources will elicit variable immune and anti-cancer
responses. We summarized the current limitations of β-
glucan research from the literature (Table 2). The limita-
tions are further complicated by the fact that many studies
on β-glucan related herbs often used crude extracts rather
than purified compounds, therefore the confounding
effects of other chemicals cannot be totally ruled out [84].
Careful selection of appropriate β-glucan products with
good pre-test quality control is essential if we want to
understand and compare the results on how β-glucans act
on our immune system and exerting anti-cancer effects. A
possibly well-defined β-glucan standard is urgently
needed in this field for controlled experiments. So far,
there are very few clinical trial data on using purified β-
glucans for cancer patients. Future studies should aim to
obtain such information so it can assist us in applying β-
glucans rationally and effectively to our cancer patients in
the future.
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